Fulcrum Therapeutics Inc
Fulcrum Therapeutics is a clinical-stage biotechnology company developing small-molecule medicines that aim to modulate gene expression for genetically defined diseases. Its lead programme targets facioscapulohumeral muscular dystrophy (FSHD), a rare muscle-wasting condition; clinical trial readouts and regulatory milestones are the key near-term catalysts. With a market capitalisation of roughly $525 million, Fulcrum is pre-commercial and relies on R&D progress rather than product revenues. Investing in Fulcrum means backing a binary, catalyst-driven story: positive trial data could materially re-rate the shares, while setbacks can be swift and severe. The company’s science is specialised and the timeline for returns can be long, so the stock tends to be volatile. This summary is general educational information only and not personal investment advice. Biotech investing carries significant risk and may not be suitable for all investors; consider your risk tolerance and consult an authorised financial adviser before making decisions.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Fulcrum Therapeutics' stock with a target price of $18.6, indicating growth potential.
Financial Health
Fulcrum Therapeutics is performing well, generating solid cash flow and maintaining a strong book value.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring FULC
Hematology Stocks | BTK Inhibitor FDA Breakthrough
Following the FDA's approval of Sanofi's Wayrilz, the first BTK inhibitor for a rare blood disorder, a new investment opportunity has emerged. This theme focuses on innovative pharmaceutical companies developing next-generation treatments for rare hematological diseases, a market poised for significant growth.
Published: August 30, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline Catalysts
Upcoming clinical readouts and regulatory milestones can create sharp share moves, though outcomes are binary and may increase volatility.
Mechanism Focus
Fulcrum’s approach targets gene-expression control in genetically defined conditions — scientifically promising but dependent on clinical validation.
Rare Disease Market
Treating rare disorders like FSHD can offer meaningful commercial opportunity if approved, yet patient populations and reimbursement dynamics are specialised.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
